A Simple and Highly Efficient Enantioselective Synthesis of (S)-Rivastigmine

Veera R. Arava, Laxminarasimhulu Gorentla, Pramod K. Dubey

.

DOI: 10.4236/ijoc.2011.12005                

Abstract

A highly efficient and convenient procedure for the enantioselective synthesis of (S)-Rivastigmine, a cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson’s disease, is accomplished by the treatment of versatile, readily accessible (S)-(-)-2-methyl-2-propanesulfinamide with 3-hydroxyacetophenone. This protocol provides high yield and excellent enantiomeric excess in short step synthesis.

Keywords

Cholinergic Agent, Enantioselective, Highly Efficient, (S)-(-)-2-Methyl-2-Propane Sulfina-mide, (S)-Rivastigmine

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	N. C. Berchtold, C. W. Cotman, “Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s,” Neurobiol. Aging. Vol. 19, No. 3, 1998, 173-189.
[2]	J. Corey-Bloom, R. Anand, J. Veach, “A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease,” Int. J. Geriatr. Psychopharmacol. Vol. 1, 1998, 55-65.
[3]	M. Rosler, R. Anand, A. Cicin-Sain, S. Gauthier, Y. Agid, P. Dal-Bianco, H. B. St?helin, R. Hartman, M. Gharabawi, “Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial,” Br. Med. J. Vol. 318, 1999, 633-640.
[4]	S. I. Finkel, “Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease,” Clin. Ther. Vol. 26, 2004, 980-990.
[5]	M. Rosler, W. Retz, P. Retz-Junginger, H. J. Dennler, “Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease,” Behav. Neurol. Vol. 11, No. 4, 1998, 211-216.
[6]	M. Emre, D. Aarsland, A. Albanese, “Rivastigmine for dementia associated with Parkinson’s disease,” N. Engl. J. Med. Vol. 315, 2004, 2509-2518.
[7]	C. Gabelli, “Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions,” Curr. Med. Res. & Opin. Vol. 19, No. 2, 2003, 69-82.
[8]	M. Wakayama, J. A. Ellman, “Recycling the tert-Butanesulfinyl Group in the Synthesis of Amines Using tert-Butanesulfinamide,” J. Org. Chem. Vol. 74, 2009, 2646-2650.
[9]	M. T. Robak, M. A. Herbage, J. A. Ellman, “Synthesis and Applications of tert-Butanesulfinamide,” Chem. Rev. Vol. 110, No. 6, 2010, 3600-3740.
[10]	A. V. Reddy, S. U. B. Rao, G. L. Narasimha, P. K. Dubey, “Improved process for the preparation of Tamsulosin Hydrochloride,” Synth. Commun. Vol. 39, 2009, 1451-1456.
[11]	A. Gaitonde, M. Mangle, S. R. Pawar, “Novel process for the preparation of aminoalkyl phenyl carbamates,” PCT, WO 2005061446, 2005; Chem. Abstr. Vol. 143, 2005, 77963.
[12]	H. Stepankova, J. Hajicek, S. Simek, “A method of production of (-)-(S)-3-[1-(dimethylamino) ethyl] phenyl-N-ethyl-N-methylcarbamate,” PCT, WO 2004037771, 2004; Chem. Abstr. Vol. 142, 2004, 6315.
[13]	M. J. V. Garrido, A. M. Montserrat, M. J. Juarez, “Method of obtaining phenyl carbamates,” PCT, WO 2007014973, 2007; Chem. Abstr. Vol. 146, 2007, 206113.
[14]	J. Feng, W-M. Chen, Sun, Ping-Hua, “Synthesis of S-(+)-rivastigmine hydrogen tartarate,” J. South. Med. Univ. Vol. 27, 2007, 177-180.
[15]	A. A. Boezio, J. Pytkowicz, A. Cote, A. B. Charette, “Asymmetric, catalytic synthesis of α-chiral amines using a novel bis(phosphine)monoxide chiral ligand,” J. Am. Chem. Soc. Vol. 125, 2003, 14260-14261.
[16]	M. Hu, F. L. Zhang, M. H. Xie, “Novel Convenient Synthesis of Rivastigmine,” Synth. Commun. Vol. 39, 2009, 1527-1533.
[17]	J. M. Sanchez, M. R. Mata, E. Busto, V. G. Fernandez, V. Gotor, “Chemoenzymatic Synthesis of Rivastigmine Based on Lipase-Catalyzed Processes,” J. Org. Chem. Vol. 74, 2009, 5304-5310.
[18]	K. Han, C. Kim, J. Park, M-J. Feng, “Chemoenzymatic synthesis of rivastigmine via dynamic kinetic resolution as a key step,” J. Org. Chem. Vol. 75, 2010, 3105-3108.
[19]	K. A. Kumar, M. A. Reddy, T. S. Kumar, B. V. Kumar, K. B. Chandrasekhar, P. R. Kumar, M. Pal, “Achiral bis-imine in combination with CoCl2: A remarkable effect on enantioselectivity of lipase-mediated acetylation of racemic secondary alcohol,” Beilstein. J. Org. Chem. Vol. 6, 2010, 1174 -1179.
[20]	M. Fuchs, D. Koszelewski, K. Tauber, W. Kroutil, K. Faber, “Chemoenzymatic asymmetric total synthesis of (S)-Rivastigmine using ω-transaminases,” Chem. Commun. Vol. 46, 2010, 5500-5502.
[21]	D. Guijarro, O. Pablo, M. Yus, “Asymmetric Synthesis of Chiral Primary Amines by Transfer Hydrogenation of N-(tert-Butanesulfinyl) ketimines,” J. Org. Chem. Vol.75, 2010, 5265-5270.
[22]	A. V. Reddy, G. Laxminarasimhulu, P. K. Dubey, “Facile enantioselective synthesis of (S)-Rivastigmine & (+)-NPS-R-568 a calcimimetic agent,” Der Pharma Chemica. Vol. 3 (1), 2011, 426-433.
[23]	A. V. Reddy, “Developing Chemical Processes for Active Pharmaceutical Ingredients (API’s)”, Third International conference and exhibition, Mumbai, India, January 10-11, 2011: Abstract No. 3.